Radioprotective effect of vitamin E on salivary glands after radioiodine therapy for differentiated thyroid cancer

Upadhyaya, Arun; Zhou, Pingping; Meng, Zhaowei; Wang, Peng; Zhang, Guizhi; Jia, Qiang; Tan, Jian; Li, Xue; Hu, Tianpeng; Liu, Na; Wang, Sen; Liu, Xiaoxia; Wang, Huiying; Zhang, Chunmei; Zhao, Fengxiao; Yan, Ziyu; Wang, Xiaoran; Zhang, Xuemeng; Wan, Zhang

doi:10.1097/mnm.0000000000000727

Cited by 22 publications

(56 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All of the 33 RAIR patients received at least two courses of 131 I therapy, whereas all of the 34 disease‐free cases received only one course of 131 I therapy. The patients were treated and monitored according to our standard procedures , which are generally in accordance with the recognized US and Chinese guidelines . Clinical data were available for all recruited cases.…”

Section: Methodsmentioning

confidence: 99%

TERT promoter mutation in primary papillary thyroid carcinoma lesions predicts absent or lower ¹³¹i uptake in metastases

et al. 2019

Self Cite

View full text Add to dashboard Cite

Genetic mutations play important roles in not only development of papillary thyroid carcinoma (PTC) but also determination of its properties. The radioactive iodine refractory (RAIR) state is a harbinger of poor outcomes for PTC. We used various statistical models to investigate the significance of TERT promoter, BRAF, and RAS mutations in distinguishing the RAIR state and their associations with 131I uptake. Mutations were examined in primary lesions of 33 RAIR cases and 34 age‐ and sex‐matched 131I‐treated cases with disease‐free status. Thyrotropin‐stimulated thyroglobulin (sTg) change, 131I uptake ability, and RAIR categories were evaluated in the RAIR cases. The prevalence of TERT mutation in the RAIR group was 24.24% (8/33), which was significantly higher than that in the disease‐free group (0/34). BRAF mutation showed a similar high prevalence in both the RAIR group (69.70%) and disease‐free group (64.71%). Among the eight TERT mutation‐positive cases, six carried both TERT and BRAF mutations. RAS mutation was detected in only one disease‐free case and in two RAIR cases. Despite a significantly higher prevalence of TERT mutations in the RAIR group, only tumor size and N1b lymph node involvement were independently associated with RAIR status. In the RAIR group, all patients carrying a TERT mutation showed maximum or increased sTg. Multivariate analyses demonstrated that the TERT mutation was associated with decreased 131I uptake and the RAIR categories of absent or weaker 131I uptake. TERT mutation constitutes a novel genetic biomarker indicating absent or weaker 131I‐avid lesions in RAIR PTC patients. It is worth evaluating the TERT status in all DTC patients undergoing 131I therapy. © 2019 IUBMB Life, 2019

show abstract

Section: Methodsmentioning

confidence: 99%

TERT promoter mutation in primary papillary thyroid carcinoma lesions predicts absent or lower ¹³¹i uptake in metastases

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…Kulkarni et al suggested that lemon juice, due to its sialagogue effect, had reduced the potential radiation absorbed dose in the parotid glands with an average of 34.2% 39 . A review of natural and synthetic compounds suggested that more studies were needed, and at the time, it was better to use natural compounds over synthetic 13,40‐43 . Botulinum toxin seems to confer radioprotective properties to salivary glands in Murine subjects by reducing glandular atrophy and periductal fibrosis during classic external radiation 44 .…”

Section: Discussionmentioning

confidence: 99%

Salivary side effects after radioiodine treatment for differentiated papillary thyroid carcinoma: Long‐term study

et al. 2020

View full text Add to dashboard Cite

Background: Although many studies focus on short-term side effects of radioiodine therapy, almost none studied long-term side effects. We assessed radioiodine long-term salivary side effects after radioiodine treatment for differentiated papillary thyroid carcinoma and compared it to short-term morbidity within the same population. Methods: A standardized self-administrated questionnaire was submitted in 2019 by patients treated with radioiodine between January 2011 and December 2012. These patients had already answered the same questionnaire 6 years before. Results: Our study showed a significant reduction for salivary side effects: discomfort in submandibular or parotid area, swelling, pain, a bad or salty taste in the mouth, allowing to get back to a "normal" diet. Conclusions: Our study suggests that a significant rate of patients will recover from I 131 therapy salivary side effects. As almost 30% of these remissions happened during our late stage follow-up, we highlight the necessity of a longterm follow-up in these patients.

show abstract

“…Kudlackova et al (23) documented that vitamin E decreases the presence of oxidative stress and antioxidant metabolites. Upadhyaya et al (15) detected the protective effect of vitamin E against the radio-iodine-induced damage in salivary glands. Acar et al (13) proposed the anti-infl ammatory and anti-fi brotic effect of vitamin E against the damage in lacrimal glands of RAI-administered rats.…”

Section: Discussionmentioning

confidence: 99%

“…Vitamin E, which is non-toxic, has been used in the treatment of diseases such as cataract, cancer and cardiovascular diseases (12). Recent studies have revealed that vitamin E has a radio-protective effect against lacrimal and salivary gland damage which occurs in patients receiving RAI treatment (13,14,15).…”

Section: Introductionmentioning

confidence: 99%

Beneficial effects of vitamin E on radioiodine induced gastrointestinal damage: an experimental and pathomorphological study

Yumuşak¹,

Sadic²,

Akbulut³

et al. 2019

BLL

View full text Add to dashboard Cite

The aim of the present study was to investigate the radioprotective effect of vitamin E in the prevention of radioiodine (RAI) induced gastrointestinal damage. METHOD: Twenty-four rats were randomly divided into three groups as follows: Group-1 was untreated control group, Group-2 was orally administered single dose of 111 MBq RAI, and Group-3 was orally administered 111 MBq RAI and 1 mL of oral vitamin E. Vitamin E was started two days before RAI administration and was continued for fi ve days once daily after RAI. Pathomorphological parameters of gastrointestinal tissues (stomach, small intestines and bowels) were measured using Hematoxylin-Eosin and Masson's trichrome staining. RESULTS: Varying degrees of infl ammation, edema, ulcer, mucosal degeneration, necrosis and fi brosis were seen in the stomach, small intestine and bowel tissues of the rats in both study groups and not in the control group. The differences were statistically signifi cant between these groups for all parameters (p < 0.05). The histopathological damage in the vitamin E treated group was signifi cantly less than the damage in the RAI only group (p < 0.05 for all pathomorphological parameters). CONCLUSION: The results of this study showed that vitamin E has a radioprotective property with antiinfl ammatory and antifi brotic effects protecting against gastrointestinal damage caused by radioiodine (Tab.

show abstract

Radioprotective effect of vitamin E on salivary glands after radioiodine therapy for differentiated thyroid cancer

Abstract: Vitamin E exerts significant protective effects on the parotid and submandibular glands after I therapy.

Cited by 22 publications

References 51 publications

TERT promoter mutation in primary papillary thyroid carcinoma lesions predicts absent or lower ¹³¹i uptake in metastases

TERT promoter mutation in primary papillary thyroid carcinoma lesions predicts absent or lower ¹³¹i uptake in metastases

Salivary side effects after radioiodine treatment for differentiated papillary thyroid carcinoma: Long‐term study

Beneficial effects of vitamin E on radioiodine induced gastrointestinal damage: an experimental and pathomorphological study

Contact Info

Product

Resources

About

Radioprotective effect of vitamin E on salivary glands after radioiodine therapy for differentiated thyroid cancer

Abstract: Vitamin E exerts significant protective effects on the parotid and submandibular glands after I therapy.

Cited by 22 publications

References 51 publications

TERT promoter mutation in primary papillary thyroid carcinoma lesions predicts absent or lower 131i uptake in metastases

TERT promoter mutation in primary papillary thyroid carcinoma lesions predicts absent or lower 131i uptake in metastases

Salivary side effects after radioiodine treatment for differentiated papillary thyroid carcinoma: Long‐term study

Beneficial effects of vitamin E on radioiodine induced gastrointestinal damage: an experimental and pathomorphological study

Contact Info

Product

Resources

About

TERT promoter mutation in primary papillary thyroid carcinoma lesions predicts absent or lower ¹³¹i uptake in metastases

TERT promoter mutation in primary papillary thyroid carcinoma lesions predicts absent or lower ¹³¹i uptake in metastases